Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Inclusion Criteria:

• Participant should have been on and agree to continue to stay on a stable dose ofbenign prostatic hyperplasia (BPH) treatment with either a) alpha blockermonotherapy or b) alpha blocker + 5 alpha reductase inhibitor.

• Participant has an International Prostate Symptom Score total score of ≥ 8

• Participant has a prostate-specific antigen level < 4 nanograms per milliliter (ng/mL), or if ≥ 4 ng/mL but ≤ 10 ng/mL, prostate cancer has been ruled out to thesatisfaction of the investigator

• Participant must have both additional qualifications based on the 3-day BladderDiary period: a) having an average of ≥ 8 but ≤ 20 micturition episodes per day overthe 3-day diary period, and (b) having an average of ≥ 3 urgency episodes per dayover the 3-day diary period

• Participant must have a post void residual volume value of < 100 mL

• Having at least 2 average nocturia episodes per night based on 3-day Bladder Diaryat baseline. Nocturia is defined as waking to pass urine during the main sleepperiod.

Exclusion Criteria:

• Participant has a history of 24-hour urine volume greater than 3,000 mL

• Has lower urinary tract pathology that could, in the opinion of the investigator, beresponsible for urgency, frequency, or incontinence

• Has a history of prostate surgery, including minimally invasive transurethral ortransrectal procedures, procedural treatments for BPH within 6 months of Screeningor has a planned prostate surgery

• Has a history of urinary retention requiring an intervention (e.g., catheterization)for any reason

• Has maximum urinary flow (Qmax) < 5.0 mL/second with a minimum voided volume of 125mL

• Has a history of or current nocturnal polyuria

• Has an active or recurrent (> 3 episodes per year) urinary tract infection byclinical symptoms or laboratory criteria (≥ 5 white blood cells/high power field [hpf] with presence of red blood cell [RBC] and/or a positive urine culture, definedas ≥ 10^5 colony forming units (CFU)/mL (i.e., 100 × 10^3 CFU/mL in a singlespecimen)

• Has uncontrolled hyperglycemia (defined as fasting blood glucose > 150 milligramsper deciliter (mg/dL) or 8.33 millimoles per liter (mmol/L) or non-fasting bloodglucose > 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the investigator, isuncontrolled

• Has uncontrolled hypertension (systolic blood pressure of ≥ 180 millimeters ofmercury (mmHg) and/or diastolic blood pressure of ≥ 100 mmHg) or has a resting heartrate (by pulse) > 100 beats per minute (min)

• Has a history of cerebral vascular accident, transient ischemic attack, unstableangina, myocardial infarction, coronary artery interventions (e.g., coronary arterybypass grafting or percutaneous coronary interventions [e.g., angioplasty, stentinsertion]), or neurovascular interventions (e.g., carotid artery stenting) within 6months prior to the Screening Visit

• Has alanine aminotransferase or aspartate aminotransferase > 2.0 times the upperlimit of normal (ULN), or bilirubin (total bilirubin) > 1.5 × ULN (or > 2.0 × ULN ifsecondary to Gilbert syndrome or pattern consistent with Gilbert syndrome)

• Has an estimated glomerular filtration rate < 30 mL/min/1.73 meters squared (m^2)

• Has a history or current evidence of any condition, therapy, laboratory abnormality,or other circumstances that might, in the opinion of the investigator, confound theresults of the study, interfere with the participant's ability to comply with thestudy procedure, or make participation in the study not in the participant's bestinterest